Xenetic presents preclinical data on DNase I with CAR T cells in murine model
Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...
Meta to start testing crowd-sourced fact-checking, based on X example, next week
Facebook and Instagram parent company Meta Platforms Inc. said Thursday it will begin testing its crowd-sourced fact-checking program, Community Notes, on March 18. It will initially based on a ...
Le Lézard1h
TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial
Clinical trial Safety Review Committee (SRC) approved opening of Cohort 4 based on favorable safety data from the three patients comprising Cohort 3; No significant safety or dose ...
Virax Biolabs Presents Data on T-Cell Dysfunction in Post-acute Infection Syndromes at the 19th World Immune Regulation Meeting
Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...
Third Arc Bio Announces First Patient Dosed in Phase 1 Clinical Trial of Lead T Cell Engager ARC101 to Treat CLDN6 Positive Cancers
Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the first ...
Scientists identify lncRNA as potential biomarker and therapeutic target for hepatocellular carcinoma
Hepatocellular carcinoma (HCC), the third leading cause of cancer-related deaths worldwide, remains one of the most ...
Labiotech.eu23h
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Physician's Weekly1d
PD-1/PD-L1 Inhibitors With Chemotherapy vs. Platinum-Based Treatment in Advanced Urothelial Cancer
The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Additional Phase 2 data for vilastobart,a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in patients with MSS CRC ...
BioNTech SE (NASDAQ:BNTX) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...
News-Medical.Net2d
Deciphering the tumor-immune interplay in endometrial carcinoma
A new review article published in Genes & Diseases sheds light on the complex molecular mechanisms through which tumor-infiltrating immune cells regulate endometrial carcinoma (EC). As one of the most ...
BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat
The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...